Neuraptive Therapeutics

Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment

WAYNE, PA — Neuraptive Therapeutics Inc. recently announced that its novel treatment for peripheral nerve injury, NTX-001, has received Orphan Drug Designation from the United States Food and Drug Administration …

Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment Read More